Dupilumab for cancer-associated refractory pruritus
Journal of Allergy and Clinical Immunology: Global · 2023-08 · 2 (3) · 100128
DOI: 10.1016/j.jacig.2023.100128 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Allergy and Clinical Immunology: Global, 2023-08. Verfasst von Aviv Talmon und 8 weiteren Autor:innen. Beteiligte Einrichtung: Allergy and Clinical Immunology Unit, Hadassah Medical Center, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Pruritus can be an intolerable symptom in patients with cancer. Type 2 inflammation, and specifically, the cytokines IL-4, IL-13, and IL-31, play major roles in the itching process. Dupilumab is an antibody against IL-4Rα, which is a common IL-4 and IL-13 receptor subunit. Blocking IL-4 and IL-13 activity reduces the synthesis of IL-31, the "itch cytokine," and receptors for these 3 cytokines are expressed on itch nerves. Dupilumab is approved for treating moderate-to-severe atopic dermatitis, of which itching is a significant symptom.
Objective
The objective of this case study was to present the initial evidence of the safety and efficacy of dupilumab as a treatment for intractable malignancy-associated pruritus in 3 patients, thereby providing a basis for further investigation in a larger cohort.
Methods
As a proof of concept, we used dupilumab in our center to treat 3 patients with intractable malignancy-associated pruritus. The first patient was a 73-year-old male with a history of prostate cancer, the second patient was a 75-year-old female with cutaneous T-cell lymphoma, and the third patient was a 32-year-old male with metastatic melanoma. All 3 patients experienced debilitating itching, which started at some stage after the malignancy had been diagnosed. Moreover, none of the 3 patients showed clinical evidence of atopic dermatitis or other causes of itching (eg, uremia or liver failure), and none of the 3 patients responded to conventional treatments for pruritus.
Results
Biweekly treatment with dupilumab led to an immediate improvement in itching, which subsided entirely after a few doses without any significant adverse effects.
Conclusion
We propose that dupilumab is a safe and effective treatment for intractable malignancy-associated pruritus, and we are currently testing it in a large cohort.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Allergy and Clinical Immunology Unit, Hadassah Medical Center, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel.
- Department of Bone Marrow Transplantation and Cancer Immunotherapy, Hadassah Medical Center, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel.
- Sharett Institute of Oncology, Hadassah Medical Center, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel.
- Harvard Medical School, Department of Surgery, Center for Engineering in Medicine and Surgery, Massachusetts General Hospital, Boston, Mass.
Zitieren
APA
Talmon, A., Elias, S., Rubin, L., Ribak, Y., Ben Dori, E., Shamriz, O., Lotem, M., Adini, I., & Tal, Y. (2023). Dupilumab for cancer-associated refractory pruritus. Journal of Allergy and Clinical Immunology: Global, 2(3), 100128. https://doi.org/10.1016/j.jacig.2023.100128
Vancouver
Talmon A, Elias S, Rubin L, Ribak Y, Ben Dori E, Shamriz O, et al. Dupilumab for cancer-associated refractory pruritus. Journal of Allergy and Clinical Immunology: Global. 2023;2(3):100128. doi:10.1016/j.jacig.2023.100128
BibTeX
@article{Talmon2023,
author = {Talmon, Aviv and Elias, Shlomo and Rubin, Limor and Ribak, Yaarit and Ben Dori, Eyal and Shamriz, Oded and Lotem, Michal and Adini, Irit and Tal, Yuval},
title = {Dupilumab for cancer-associated refractory pruritus},
journal = {Journal of Allergy and Clinical Immunology: Global},
year = {2023},
volume = {2},
number = {3},
pages = {100128},
doi = {10.1016/j.jacig.2023.100128}
}
EUVIMED